List of Belbuca drug patents

Belbuca is owned by Bdsi.

Belbuca contains Buprenorphine Hydrochloride.

Belbuca has a total of 3 drug patents out of which 0 drug patents have expired.

Belbuca was authorised for market use on 23 October, 2015.

Belbuca is available in film;buccal dosage forms.

Belbuca can be used as management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, treatement of pain by transmucosal delivery of buprenorphine.

The generics of Belbuca are possible to be released after 21 December, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8147866 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(4 years from now)

US9655843 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(4 years from now)

US9901539 BDSI Transmucosal drug delivery devices for use in chronic pain relief
Dec, 2032

(9 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 October, 2015

Treatment: Treatement of pain by transmucosal delivery of buprenorphine; Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: FILM;BUCCAL

How can I launch a generic of BELBUCA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic